Moderna's cancer-cure mystery and optimism are the conditions that drive big stock moves. Its theme is now hot to trade, alongside related stocks. CoreWeave's 2025 AI data-center IPO rode similar uncertainty about AI revenue while AI was hot; it now faces AI-spending worries. x.com 

Moderna is extremely attractive because curing cancer is a big story, but more consolidation is likely first. The weekly chart shows a wide gap between price and the upper Bollinger Band, so volatility may need another week or two to ebb before the stock possibly starts moving higher. x.com 

Moderna's customer options positioning was not bullish, and the stock subsequently flushed 20%. WizOfOps described the top 10 trades as only modestly bearish, with no solid consensus among the customers dominating the flow. x.com 

Biotech is drawing some of the largest long-term buying ever into the SPDR S&P Biotech ETF as it pushes toward its 2021 all-time high. Heavy buy volume, including another historic dollar-volume spike last week, matters more than short-term uncertainty, and the selling has been inefficient. If price loses $154.20 again, the bear case comes back into play. x.com 

Moderna looks like a logical play on plague-outbreak concerns, though this is outside areas of expertise. A Russian lab worker's sudden death has raised fears of a plague crisis, per Zero Hedge, with the Trump team monitoring the outbreak, and the stock is acting well. x.com 

Moderna's data catalyst is done, and it won't get an early stop in RCC. That makes it a good short here, with the story over until at least next summer. x.com 

Moderna looks likely to stay relatively stable above its gap-up price into next year, as big buyers return. A $6M sale of March 2027 $110 puts bets on exactly that, which seems logical. Yesterday's $30B was the second-largest dollar buy volume ever for the stock, after buy volumes had already re-emerged; January's buying, the largest since Q2 2024, came when the stock was above $100, versus about $50 now. x.com  x.com 

Biotech is back. A quoted report says lab monkey prices in China have surged to about $26,000 each as the biotech boom overwhelms supply. x.com 

Moderna looks slightly vulnerable after tripling in two weeks without follow-up news. A wedge pattern is forming with lower highs. If it holds $140, buyers could step in and drive another bounce back to $150+. x.com 

Amgen shows signs of continued institutional buying and potential short-term strength. A $2.3 billion print and a $26 million roll into deep in-the-money calls both point that way, and its weekly entry candle resembles Union Pacific's. x.com  x.com